Overview
OHMX delivers advanced multi-omics and bioinformatics services that transform complex data into actionable insights for research and clinical discovery. The company offers sequencing solutions, molecular testing, biomarker services, proteomics, and data analysis across expertise areas including cell gene therapy, infectious diseases, immunology, and oncology.
Key people
In the news
- Every project is different, and at OHMX.bio, we are happy to be on the forefront of science, collaborating with academia. Thank you for the kind words, Thomas. 🙏
- 𝗢𝗛𝗠𝗫.𝗯𝗶𝗼 𝗶𝘀 𝗵𝗲𝗮𝗱𝗶𝗻𝗴 𝘁𝗼 𝗕𝗶𝗼𝗺𝗮𝗿𝗸𝗲𝗿𝘀, 𝗖𝗗𝘅 & 𝗣𝗿𝗲𝗰𝗶𝘀𝗶𝗼𝗻 𝗠𝗲𝗱𝗶𝗰𝗶𝗻𝗲 𝟮𝟬𝟮𝟲 𝗶𝗻 𝗕𝗮𝘀𝗲𝗹. On 13 and 14 October, Europe's leading biomarker conference brings together pharma, biotech, academic, and regulatory leaders at the Congress Center Basel. This year's edition runs alongside NextGen Omics, Tech & Data Europe, covering four programmes across two days: from biomarker discovery and CDx development to computational pathology, AI, and precision diagnostics. Come find us at booth 52 if you
- 𝗪𝗚𝗦. 𝗪𝗘𝗦. 𝗥𝗡𝗔-𝘀𝗲𝗾. 𝗦𝗺𝗮𝗹𝗹 𝗥𝗡𝗔. 𝗕𝗶𝘀𝘂𝗹𝗳𝗶𝘁𝗲 𝘀𝗲𝗾𝘂𝗲𝗻𝗰𝗶𝗻𝗴. 𝗢𝗻𝗲 𝗽𝗹𝗮𝘁𝗳𝗼𝗿𝗺 𝗱𝗼𝗲𝘀𝗻'𝘁 𝗰𝗼𝘃𝗲𝗿 𝗲𝘃𝗲𝗿𝘆𝘁𝗵𝗶𝗻𝗴, 𝗯𝘂𝘁 𝗼𝘂𝗿 𝘀𝗵𝗼𝗿𝘁-𝗿𝗲𝗮𝗱 𝗡𝗚𝗦 𝗼𝗳𝗳𝗲𝗿𝗶𝗻𝗴 𝗰𝗼𝗺𝗲𝘀 𝗰𝗹𝗼𝘀𝗲. At OHMX.bio, short-read sequencing runs on the Illumina iSeq 100 and Element Biosciences AVITI. The AVITI delivers read accuracy exceeding 90% at Q40, making it well-suited for variant detection, clinical research samples, and biomarker validation workflows where data integrity is
- In or around Lausanne on the 30th of September? Gerben Menschaert, me and our partners from BioLizard are organising a Breakfast meeting where we will present both sides of every -omics project: data generation and data analysis! Join us to learn how to allign those two parts for the best outcome. Be sure to register and see you there 👋
- What happens to your data between the wet lab and the decisions it ultimately supports? On 𝗦𝗲𝗽𝘁𝗲𝗺𝗯𝗲𝗿 𝟯𝟬, BioLizard and OHMX.bio are bringing together scientists and bioinformatics experts in Lausanne for a morning focused on the data lifecycle. We’re looking forward to the discussion with Alexander Koch & Karina Saakyan from BioLizard and Gerben Menschaert & Joannes van Cann, PhD from OHMX.bio. 📍 𝗔𝗹𝗮𝗻𝗶𝗻𝗲 𝗕𝘂𝗶𝗹𝗱𝗶𝗻𝗴, 𝗕𝗶𝗼𝗽𝗼𝗹𝗲, 𝗟𝗮𝘂𝘀𝗮𝗻𝗻𝗲 🗓 𝗦𝗲𝗽𝘁𝗲𝗺𝗯𝗲𝗿 𝟯𝟬, 𝟮𝟬𝟮𝟲 | 𝟵:𝟬𝟬–𝟭𝟭:𝟯𝟬 The
- 𝗢𝗛𝗠𝗫.𝗯𝗶𝗼 𝗮𝗻𝗱 BioLizard 𝗮𝗿𝗲 𝗵𝗼𝘀𝘁𝗶𝗻𝗴 𝗮 𝗯𝗿𝗲𝗮𝗸𝗳𝗮𝘀𝘁 𝘀𝗲𝘀𝘀𝗶𝗼𝗻 𝗶𝗻 𝗟𝗮𝘂𝘀𝗮𝗻𝗻𝗲 𝗼𝗻 𝗦𝗲𝗽𝘁𝗲𝗺𝗯𝗲𝗿 𝟯𝟬. A focused morning on multi-omics and bio-IT: how data, biology, and bioinformatics come together to drive better research outcomes. Joining from OHMX.bio: Gerben Menschaert, co-founder and CSO, and Joannes van Cann, PhD. From BioLizard: Alexander Koch and Karina Saakyan. Interested in joining? Register here: https://lnkd.in/eYiVUqqG 📅 September 30, 2026 | 9:00–11:30 📍 Alanine Building,
- Steven Verbruggen 𝗶𝘀 𝗼𝗻 𝘁𝗵𝗲 𝗳𝗹𝗼𝗼𝗿 𝗮𝘁 𝗘𝗖𝗖𝗕 𝟮𝟬𝟮𝟲 𝗶𝗻 𝗚𝗲𝗻𝗲𝘃𝗮. Europe's leading computational biology conference is happening, and there's no shortage of good conversations around genomics, AI, and data-driven health. Let's connect if you're attending. #ECCB2026 #Bioinformatics #Genomics #ComputationalBiology #LifeSciences #Biotech #Switzerland
- 𝗠𝗼𝘀𝘁 𝗲𝗮𝗿𝗹𝘆 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝘁𝗿𝗶𝗮𝗹 𝗯𝗶𝗼𝗺𝗮𝗿𝗸𝗲𝗿 𝗳𝗮𝗶𝗹𝘂𝗿𝗲𝘀 𝗱𝗼𝗻'𝘁 𝘀𝘁𝗮𝗿𝘁 𝗶𝗻 𝘁𝗵𝗲 𝗹𝗮𝗯. They start with a sampling window that's too broad, a tube type that wasn't specified, or a baseline and on-treatment sample processed in separate batches. Pre-analytics is where biomarker quality is won or lost. Read our blog below to learn more. 👉 https://lnkd.in/eqQXnxSC #ClinicalTrials #Biomarkers #PhaseI #Biotech #LifeSciences #DrugDevelopment
Something wrong or missing? Send an update. Fixed within 24 hours.